Genentech Agrees to Acquire Seragon to Strengthen Breast Cancer Pipeline
Read about Genentech’s planned acquisition of Seragon.
Medicine for people with chronic idiopathic urticaria (CIU), a form of chronic hives.
Genentech is committed to ensuring price is not a barrier to access for patients. Learn about our programs.
Announcing Sunshine Track
Physicians can now use our secure online portal to review Sunshine-reportable payments before they are reported to the government.
Search for jobs. Learn more about what is currently available. And then apply for the position at Genentech that’s right for you.
Clinical Trial Data Sharing
As part of our commitment to sharing data from our clinical trials, researchers may now request access to analyzable patient-level data. Learn more.
We’re working together to shape the future of biotech. Take a look inside Genentech.
Our pipeline includes new molecular entities that address serious unmet medical needs.
Collaborating With Managed Care
Insights on trends, events, and therapeutic advances. Learn more at Genentech-Forum.com.
Genentech named FORTUNE Best Company
We've been named to FORTUNE's "100 Best Companies to Work For" list for the 16th year in a row.
Building Towards a Sustainable Future
In an effort to increase sustainability practices on our SSF campus, we've joined the US Green Buildings Challenge.
At Genentech, our t-shirts represent our stories - about our people, our community, and ultimately about the impact of biotechnology on medicine.
Find links to info and resources on each of our medicines, including prescribing information, material data safety sheets, medication guides, and healthcare provider letters.
Partnering is a relatively new phenomenon for biopharmaceutical companies, but collaboration has been part of Genentech’s DNA from the beginning.
Get to Know Us
How well do you know Genentech? Learn about who we are outside of the lab.